Emanuela Boveri

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4756838/publications.pdf

Version: 2024-02-01

80 papers	6,300 citations	94433 37 h-index	74163 75 g-index
80 all docs	80 docs citations	80 times ranked	6024 citing authors

#	Article	IF	Citations
1	JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood, 2014, 123, 1544-1551.	1.4	507
2	Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study. Journal of Clinical Oncology, 2011, 29, 3179-3184.	1.6	441
3	Clinical significance of somatic mutation in unexplained blood cytopenia. Blood, 2017, 129, 3371-3378.	1.4	379
4	SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood, 2015, 126, 233-241.	1.4	361
5	Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood, 2014, 124, 1062-1069.	1.4	340
6	Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in WaldenstrÃ¶mâ€™s macroglobulinemia and related lymphoid neoplasms. Blood, 2013, 121, 2522-2528.	1.4	290
7	Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica, 2008, 93, 1645-1651.	3.5	241
8	Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood, 2006, 107, 3676-3682.	1.4	236
9	Clinical Relevance of Bone Marrow Fibrosis and CD34-Positive Cell Clusters in Primary Myelodysplastic Syndromes. Journal of Clinical Oncology, 2009, 27, 754-762.	1.6	225
10	A prognostic model to predict survival in 867 World Health Organizationâ€“defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood, 2012, 120, 1197-1201.	1.4	222
11	Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. Blood, 2014, 124, 1513-1521.	1.4	222
12	Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood, 2006, 107, 4643-4649.	1.4	217
13	The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. Blood, 2012, 119, 188-191.	1.4	150
14	Twenty-one cases of blastic plasmacytoid dendritic cell neoplasm: focus on biallelic locus 9p21.3 deletion. Blood, 2011, 118, 4591-4594.	1.4	140
15	Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Blood, 2009, 114, 3538-3545.	1.4	135
16	Familial Chronic Myeloproliferative Disorders: Clinical Phenotype and Evidence of Disease Anticipation. Journal of Clinical Oncology, 2007, 25, 5630-5635.	1.6	130
17	Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles. Cancer, 2004, 100, 107-115.	4.1	121
18	A dynamic prognostic model to predict survival in postâ€“polycythemia vera myelofibrosis. Blood, 2008, 111, 3383-3387.	1.4	108

#	Article	IF	Citations
19	Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. Blood, 2012, 119, 2239-2241.	1.4	90
20	Pattern of somatic mutations in patients with WaldenstrÃ¶m macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. Haematologica, 2017, 102, 2077-2085.	3.5	90
21	Littoral Cell Angiosarcoma of the Spleen Case Report with Immunohistochemical and Ultrastructural Analysis. American Journal of Surgical Pathology, 1995, 19, 1203-1208.	3.7	86
22	Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. Blood, 2013, 121, 4388-4395.	1.4	83
23	JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. Cancer, 2006, 107, 2206-2211.	4.1	82
24	Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia. Haematologica, 2013, 98, 635-639.	3.5	75
25	CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis. Blood, 2014, 123, 2416-2419.	1.4	66
26	Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients. Haematologica, 2011, 96, 454-458.	3.5	65
27	Nongastric Marginalâ€Zone Bâ€Cell MALT Lymphoma: Prognostic Value of Disease Dissemination. Oncologist, 2006, 11, 285-291.	3.7	63
28	Primary cutaneous large B-cell lymphoma of the leg: Histogenetic analysis of a controversial clinicopathologic entity. Human Pathology, 2002, 33, 937-943.	2.0	62
29	Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome. Leukemia, 2019, 33, 2495-2505.	7.2	61
30	Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations. British Journal of Haematology, 2008, 140, 162-168.	2.5	60
31	Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS. Haematologica, 2011, 96, 167-170.	3.5	60
32	Relationship between clone metrics and clinical outcome in clonal cytopenia. Blood, 2021, 138, 965-976.	1.4	58
33	MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance. Blood, 2013, 122, 2284-2285.	1.4	56
34	Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms. Modern Pathology, 2014, 27, 814-822.	5.5	48
35	Nodal marginal zone lymphoma: current knowledge and future directions of an heterogeneous disease. European Journal of Haematology, 2009, 83, 165-174.	2.2	47
36	Efficacy of Ruxolitinib in Chronic Eosinophilic Leukemia Associated With a PCM1-JAK2 Fusion Gene. Journal of Clinical Oncology, 2013, 31, e269-e271.	1.6	47

#	Article	IF	Citations
37	Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. Oncotarget, 2017, 8, 101735-101744.	1.8	45
38	Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma. Blood, 2014, 123, 1836-1849.	1.4	37
39	Splenic marginal zone cell lymphoma: Report of an indolent variant without massive splenomegaly presumably representing an early phase of the disease. Human Pathology, 1995, 26, 39-46.	2.0	35
40	Dyspnea secondary to pulmonary hematopoiesis as presenting symptom of myelofibrosis with myeloid metaplasia. American Journal of Hematology, 2006, 81, 124-127.	4.1	35
41	Cutaneous CD30+ lymphoproliferative disorders: Expression of bcl-2 and proteins of the tumor necrosis factor receptor superfamily. Human Pathology, 1998, 29, 1223-1230.	2.0	33
42	CD146+ bone marrow osteoprogenitors increase in the advanced stages of primary myelofibrosis. Haematologica, 2009, 94, 127-130.	3.5	33
43	Depletion of circulating IgM memory B cells predicts unfavourable outcome in COVID-19. Scientific Reports, 2020, 10, 20836.	3.3	32
44	Marginal zone-related neoplasms of splenic and nodal origin. Haematologica, 2003, 88, 80-93.	3.5	31
45	Splenic marginal zone lymphoma: Clinical clustering of immunoglobulin heavy chain repertoires. Blood Cells, Molecules, and Diseases, 2009, 42, 286-291.	1.4	30
46	Assessment of bone marrow involvement in nonâ€Hodgkinâ€™s lymphomas: comparison between histology and flow cytometry. European Journal of Haematology, 2010, 85, 405-415.	2.2	30
47	Primary gastric CD30 (Ki-1)-positive large cell non-Hodgkin's lymphomas. A clinicopathologic analysis of six cases. Cancer, 1994, 73, 541-549.	4.1	26
48	Ruxolitinib treatment and risk of Bâ€cell lymphomas in myeloproliferative neoplasms. American Journal of Hematology, 2019, 94, E185-E188.	4.1	26
49	Positive predictive value for malignancy of uncertain malignant potential (B3) breast lesions diagnosed on vacuum-assisted biopsy (VAB): is surgical excision still recommended?. European Radiology, 2021, 31, 920-927.	4.5	23
50	Distinctive Clinical and Histological Features of WaldenstrÃ¶m's Macroglobulinemia and Splenic Marginal Zone Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 103-105.	0.4	22
51	High-resolution genome-wide array comparative genomic hybridization in splenic marginal zone B-cell lymphoma. Human Pathology, 2009, 40, 1628-1637.	2.0	21
52	Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network. American Journal of Hematology, 2019, 94, 1193-1199.	4.1	18
53	CD5â˜ diffuse large B-cell lymphoma with peculiar cyclin D1+ phenotype. Pathologic and molecular characterization of a single case. Human Pathology, 2011, 42, 1204-1208.	2.0	15
54	European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica 2012;97(3):360-5 - Comment. Haematologica, 2012, 97, e5-e6.	3.5	15

#	Article	IF	Citations
55	Diagnosis and management of prefibrotic myelofibrosis. Expert Review of Hematology, 2018, 11, 537-545.	2.2	13
56	A riskâ€stratification model based on the initial concentration of the serum monoclonal protein and <scp>MYD</scp>88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to WaldenstrÃ¶m macroglobulinaemia or other lymphoproliferative disorders. British Journal of Haematology, 2019, 187, 441-446.	2.5	13
57	CD56/Neural Cell Adhesion Molecule Expression in Primary Extranodal Ki-1/CD30+ Lymphoma. American Journal of Dermatopathology, 1997, 19, 384-390.	0.6	13
58	Parental origin of the deletion del(20q) in ShwachmanâDiamond patients and loss of the paternally derived allele of the imprinted L3MBTL1 gene. Genes Chromosomes and Cancer, 2017, 56, 51-58.	2.8	12
59	Nijmegen Breakage Syndrome-associated T-cell-rich B-cell Lymphoma: Case Report. Pediatric and Developmental Pathology, 2000, 3, 264-270.	1.0	9
60	The Italian Mastocytosis Registry: 6-year experience from a hospital-based registry. Future Oncology, 2018, 14, 2713-2723.	2.4	9
61	CD3+ T large granular lymphocyte leukaemia in a HIV+, HCV+, HBV+ patient. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2009, 454, 349-351.	2.8	8
62	Particulate cytoplasmic structures with high concentration of ubiquitin-proteasome accumulate in myeloid neoplasms. Journal of Hematology and Oncology, 2015, 8, 71.	17.0	8
63	Targeted nextâgeneration sequencing reveals molecular heterogeneity in nonâchronic lymphocytic leukemia clonal Bâcell lymphocytosis. Hematological Oncology, 2020, 38, 689-697.	1.7	7
64	Validation of cytogenetic-based risk stratification in primary myelofibrosis. Blood, 2010, 115, 2719-2720.	1.4	6
65	Cutaneous involvement by postâpolycythemia vera myelofibrosis. American Journal of Hematology, 2014, 89, 448-448.	4.1	6
66	Massive mediastinal enlargement due to extramedullary haematopoiesis in a patient with MYH9 -related thrombocytopenia. British Journal of Haematology, 2017, 178, 10-10.	2.5	5
67	First Case of an AIDS Patient With Systemic Mast Cell Disease Associated With Eosinophilia FIP1-Positive Treated With Imatinib Mesylate Therapy. Journal of Clinical Oncology, 2006, 24, e6-e7.	1.6	4
68	An Insidious Presentation of Splenic Marginal Zone Lymphoma. Clinical Lymphoma and Myeloma, 2007, 7, 432-433.	1.4	3
69	c.428Tâ€‰>â€‰C (p.V143A) homozygous mutation in TP53 gene as a possible mechanism of resistance to trastuzumab therapy in gastric cancer. Acta OncolÃ³gica, 2016, 55, 1373-1375.	1.8	3
70	Vascular endothelial growth factor overexpression in myelodysplastic syndrome bone marrow cells: biological and clinical implications. Leukemia and Lymphoma, 2017, 58, 1711-1720.	1.3	3
71	Telangiectasia macularis eruptiva perstans: a neglected type of mastocytosis with exclusively cutaneous involvement? A case series. European Journal of Dermatology, 2019, 29, 174-178.	0.6	3
72	Histopathological and immunohistochemical evaluation of bone marrow biopsy in myelodysplastic syndromes. International Journal of Hematologic Oncology, 2013, 2, 219-228.	1.6	1

#	Article	IF	Citations
73	Acute megakaryoblastic leukemia with a novel GATA1 mutation in a second trimester stillborn fetus with trisomy 21. Leukemia and Lymphoma, 2021, 62, 2276-2279.	1.3	1
74	Splenic Marginal Zone B-Cell Lymphoma: Clinical Clustering of Immunoglobulin Heavy Chain Repertoires.. Blood, 2008, 112, 1775-1775.	1.4	1
75	Prevalence and Clinical Significance of the MYD88 (L265P) Somatic Mutation in Patients with Waldenstroˆm Macroglobulinemia, IgM-Monoclonal Gammopathy of Undetermined Significance or Other Mature B-Cell Neoplasms.. Blood, 2012, 120, 2667-2667.	1.4	1
76	Aberrant phenotype of plasmacytoid monocytesin acute myeloid leukemia. American Journal of Hematology, 2008, 83, 428-429.	4.1	0
77	Systemic mastocytosis and lymphoplasmacytic lymphoma: an unusual and intriguing form of SM-AHN. Leukemia and Lymphoma, 2021, 62, 1782-1785.	1.3	0
78	Relationship Between Granulocyte JAK2 (V617F) Mutant Allele Burden and Risk of Progression to Myelofibrosis in Polycythemia Vera: a Prospective Study of 338 Patients.. Blood, 2009, 114, 751-751.	1.4	0
79	Bone Marrow Biopsy Revision According to WHO Criteria in 272 Patients of the Registro Italiano Trombocitemia (RIT): Preliminary Report On Clinical and Histopathological Implications.. Blood, 2009, 114, 4974-4974.	1.4	0
80	Constant Activation of the RAF-MEK-ERK Pathway As a Diagnostic and Therapeutic Target in Hairy Cell Leukemia.. Blood, 2012, 120, 2657-2657.	1.4	0